Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | TTK | P33981 | 6/20 | 0.40 |
| ▸ | CDK2 | P24941 | 6/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.40 |
| ▸ | AURKA | O14965 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL609443 | 0.88 | HCAR3 (0.48) | HPGDHCAR3 | |
| SCHEMBL12602957 | 0.87 | HPGD (0.38) | GRM5HPGDHCAR3 | |
| SCHEMBL611354 | 0.85 | MAPK1 (0.42) | GRM5TYK2JAK2JAK1JAK3 | |
| SCHEMBL610958 | 0.82 | HPGD (0.57) | GRM5TYK2HPGD | |
| SCHEMBL15906434 | 0.81 | FASN (0.51) | GRM5CDK2HPGD | |
| SCHEMBL12602961 | 0.81 | GRM5 (0.60) | GRM5TYK2HPGD | |
| SCHEMBL609572 | 0.79 | KDM4E (0.56) | GRM5TYK2HPGDLRRK2 | |
| SCHEMBL29925224 | 0.79 | KDM4E (0.56) | GRM5TYK2HPGDLRRK2 | |
| SCHEMBL608992 | 0.78 | HPGD (0.48) | GRM5HPGDKMT2A | |
| SCHEMBL15101753 | 0.78 | PKM (0.47) | TYK2JAK2JAK1JAK3HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2744804-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2017-05-17 | — | — | EP | disclosed |
| US-8940741-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2015-01-27 | — | — | US | disclosed |
| EP-2603500-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2014-11-19 | — | — | EP | disclosed |
| US-8889682-B2 | Inhibitors of bruton'S tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2014-11-18 | — | — | US | disclosed |
| EP-2744804-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F.HOFFMANN-LA ROCHE AG (CH) | 2014-06-25 | — | — | EP | disclosed |
| US-20130178461-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-8481540-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2603500-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F.HOFFMANN-LA ROCHE AG (CH) | 2013-06-19 | — | — | EP | disclosed |
| US-20130045965-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. | 2013-02-21 | — | — | US | disclosed |
| WO-2013024078-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-21 | — | — | WO | disclosed |
| WO-2012020008-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | WO | disclosed |
| US-20120040949-A1 | Inhibitors of Bruton's Tyrosine Kinase | BERTHEL STEVEN JOSEPH (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040949-A1 | Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LYN | GRM5 3767/4885TYK2 7/4885JAK2 44/4885 |
| US-20130045965-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | GRM5 4527/4885TYK2 14/4885JAK2 35/4885 |
| US-20130178461-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | GRM5 3767/4885TYK2 7/4885JAK2 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.